Literature DB >> 31083768

Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD).

Simon D Brandt1, Pierce V Kavanagh2, Folker Westphal3, Alexander Stratford4, Simon P Elliott5, Geraldine Dowling2,6, Jason Wallach7, Adam L Halberstadt8.   

Abstract

The psychedelic properties of lysergic acid diethylamide (LSD) have captured the imagination of researchers for many years and its rediscovery as an important research tool is evidenced by its clinical use within neuroscientific and therapeutic settings. At the same time, a number of novel LSD analogs have recently emerged as recreational drugs, which makes it necessary to study their analytical and pharmacological properties. One recent addition to this series of LSD analogs is 1-butanoyl-LSD (1B-LSD), a constitutional isomer of 1-propanoyl-6-ethyl-6-nor-lysergic acid diethylamide (1P-ETH-LAD), another LSD analog that was described previously. This study presents a comprehensive analytical characterization of 1B-LSD employing nuclear magnetic resonance spectroscopy (NMR), low- and high-resolution mass spectrometry platforms, gas- and liquid chromatography (GC and LC), and GC-condensed phase and attenuated total reflection infrared spectroscopy analyses. Analytical differentiation of 1B-LSD from 1P-ETH-LAD was straightforward. LSD and other serotonergic hallucinogens induce the head-twitch response (HTR) in rats and mice, which is believed to be mediated largely by 5-HT2A receptor activation. HTR studies were conducted in C57BL/6J mice to assess whether 1B-LSD has LSD-like behavioral effects. 1B-LSD produced a dose-dependent increase in HTR counts, acting with ~14% (ED50  = 976.7 nmol/kg) of the potency of LSD (ED50  = 132.8 nmol/kg). This finding suggests that the behavioral effects of 1B-LSD are reminiscent of LSD and other serotonergic hallucinogens. The possibility exists that 1B-LSD serves as a pro-drug for LSD. Further investigations are warranted to confirm whether 1B-LSD produces LSD-like psychoactive effects in humans.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  5-HT2A receptor; LSD; lysergamides; new psychoactive substances; psychedelics

Mesh:

Substances:

Year:  2019        PMID: 31083768      PMCID: PMC6899222          DOI: 10.1002/dta.2613

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  24 in total

1.  A clinical comparison of three related hallucinogens.

Authors:  S MALITZ; B WILKENS; W C ROEHRIG; P H HOCH
Journal:  Psychiatr Q       Date:  1960-04

Review 2.  Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model.

Authors:  Clint E Canal; Drake Morgan
Journal:  Drug Test Anal       Date:  2012-04-19       Impact factor: 3.345

3.  Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior.

Authors:  Javier González-Maeso; Noelia V Weisstaub; Mingming Zhou; Pokman Chan; Lidija Ivic; Rosalind Ang; Alena Lira; Maria Bradley-Moore; Yongchao Ge; Qiang Zhou; Stuart C Sealfon; Jay A Gingrich
Journal:  Neuron       Date:  2007-02-01       Impact factor: 17.173

4.  Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response.

Authors:  Adam L Halberstadt; Mark A Geyer
Journal:  Neuropharmacology       Date:  2013-09-04       Impact factor: 5.250

Review 5.  Effect of Hallucinogens on Unconditioned Behavior.

Authors:  Adam L Halberstadt; Mark A Geyer
Journal:  Curr Top Behav Neurosci       Date:  2018

6.  Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD).

Authors:  Simon D Brandt; Pierce V Kavanagh; Folker Westphal; Alexander Stratford; Simon P Elliott; Khoa Hoang; Jason Wallach; Adam L Halberstadt
Journal:  Drug Test Anal       Date:  2015-10-12       Impact factor: 3.345

7.  Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA).

Authors:  Adam L Halberstadt; Landon M Klein; Muhammad Chatha; Laura B Valenzuela; Alexander Stratford; Jason Wallach; David E Nichols; Simon D Brandt
Journal:  Psychopharmacology (Berl)       Date:  2018-10-08       Impact factor: 4.530

8.  Comparison of the behavioral responses induced by phenylalkylamine hallucinogens and their tetrahydrobenzodifuran ("FLY") and benzodifuran ("DragonFLY") analogs.

Authors:  Adam L Halberstadt; Muhammad Chatha; Alexander Stratford; Matthias Grill; Simon D Brandt
Journal:  Neuropharmacology       Date:  2018-10-29       Impact factor: 5.250

9.  N-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT2 Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues.

Authors:  David E Nichols; M Flori Sassano; Adam L Halberstadt; Landon M Klein; Simon D Brandt; Simon P Elliott; Wolfgang J Fiedler
Journal:  ACS Chem Neurosci       Date:  2015-01-21       Impact factor: 4.418

Review 10.  Modern Clinical Research on LSD.

Authors:  Matthias E Liechti
Journal:  Neuropsychopharmacology       Date:  2017-04-27       Impact factor: 7.853

View more
  11 in total

1.  Return of the lysergamides. Part VII: Analytical and behavioural characterization of 1-valeroyl-d-lysergic acid diethylamide (1V-LSD).

Authors:  Simon D Brandt; Pierce V Kavanagh; Folker Westphal; Benedikt Pulver; Kathleen Morton; Alexander Stratford; Geraldine Dowling; Adam L Halberstadt
Journal:  Drug Test Anal       Date:  2021-12-08       Impact factor: 3.234

2.  Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species.

Authors:  Adam L Halberstadt; Muhammad Chatha; Adam K Klein; Jason Wallach; Simon D Brandt
Journal:  Neuropharmacology       Date:  2020-01-07       Impact factor: 5.273

3.  Automated detection of the head-twitch response using wavelet scalograms and a deep convolutional neural network.

Authors:  Adam L Halberstadt
Journal:  Sci Rep       Date:  2020-05-20       Impact factor: 4.379

Review 4.  New psychoactive substances: a review and updates.

Authors:  Abu Shafi; Alex J Berry; Harry Sumnall; David M Wood; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2020-12-17

Review 5.  1H Nuclear Magnetic Resonance: A Future Approach to the Metabolic Profiling of Psychedelics in Human Biofluids?

Authors:  Sylvana Vilca-Melendez; Malin V Uthaug; Julian L Griffin
Journal:  Front Psychiatry       Date:  2021-12-13       Impact factor: 4.157

6.  Analytical profile of N-ethyl-N-cyclopropyl lysergamide (ECPLA), an isomer of lysergic acid 2,4-dimethylazetidide (LSZ).

Authors:  Simon D Brandt; Pierce V Kavanagh; Folker Westphal; Alexander Stratford; Simon P Elliott; Geraldine Dowling; Adam L Halberstadt
Journal:  Drug Test Anal       Date:  2020-09-17       Impact factor: 3.234

7.  Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD).

Authors:  Adam L Halberstadt; Muhammad Chatha; Adam K Klein; John D McCorvy; Markus R Meyer; Lea Wagmann; Alexander Stratford; Simon D Brandt
Journal:  Neuropharmacology       Date:  2019-11-19       Impact factor: 5.273

8.  Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD).

Authors:  Simon D Brandt; Pierce V Kavanagh; Folker Westphal; Alexander Stratford; Anna U Odland; Adam K Klein; Geraldine Dowling; Nicola M Dempster; Jason Wallach; Torsten Passie; Adam L Halberstadt
Journal:  Drug Test Anal       Date:  2020-04-20       Impact factor: 3.234

Review 9.  Designer drugs: mechanism of action and adverse effects.

Authors:  Dino Luethi; Matthias E Liechti
Journal:  Arch Toxicol       Date:  2020-04-06       Impact factor: 5.153

10.  Identification of 1-Butyl-Lysergic Acid Diethylamide (1B-LSD) in Seized Blotter Paper Using an Integrated Workflow of Analytical Techniques and Chemo-Informatics.

Authors:  Emmanouil Tsochatzis; Joao Alberto Lopes; Fabiano Reniero; Margaret Holland; Jenny Åberg; Claude Guillou
Journal:  Molecules       Date:  2020-02-07       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.